Quick Answer
BIOREGENX, INC. reported Cash and Equivalents of $58.4 thousand for fiscal year 2024.
BIOREGENX, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $58.4K | -53.4% |
| 2023 | $125.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $70.1K | — | +22.1% |
| June 30, 2024 | $57.4K | — | -54.2% |
| December 31, 2023 | $125.4K | — | — |
- BIOREGENX, INC. showed a decrease of -53.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2024 period, BIOREGENX, INC.’s cash and equivalents has declined by 53.4% (from $125.4 thousand to $58.4 thousand).
- The most recent figure is from BIOREGENX, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: